3 Research Led Pharma Company, Chronic and Acute Therapy Leader and Largest Indian Pharma Group Stocks With a Strong Future Roadmap: Glenmark Pharmaceuticals, Mankind Pharma and Sun Pharma

Research, chronic brand and leader pharma give investors a way to track businesses that sit close to everyday demand in India. Glenmark Pharmaceuticals, Mankind Pharma and Sun Pharma cover a research led pharma company, a chronic and acute therapy leader and the largest Indian pharma group.

This list covers three research, chronic brand and leader pharma with complete current figures: Glenmark Pharmaceuticals, Mankind Pharma and Sun Pharma. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Research, Chronic Brand and Leader Pharma?

Research, chronic brand and leader pharma are listed pharmaceutical companies that sell branded generics in India and emerging markets, lead in chronic and acute therapies through a wide field force and run branded, generics and specialty businesses. Their earnings depend on brand strength, launches and approvals.

Research, Chronic Brand and Leader Pharma at a Glance

On valuation, Glenmark Pharmaceuticals and Sun Pharma trade at a P/E below the industry P/E, while Mankind Pharma trades above it, which reflects the growth the market already expects. Readers comparing research, chronic brand and leader pharma should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in research, chronic brand and leader pharma can use the coming numbers to test whether growth is holding.

Why Do Research, Chronic Brand and Leader Pharma Have a Strong Roadmap in India?

Research, chronic brand and leader pharma have a strong roadmap in India because chronic disease care, rising healthcare spending and wider access to medicines in smaller towns keep widening the market for Indian pharmaceutical firms.

• Brand strength. Trusted names drive repeat prescriptions.
• Wider reach. Field forces serve smaller towns.
• Specialty growth. New launches broaden the product mix.

Why Glenmark Pharmaceuticals Features Among These Research, Chronic Brand and Leader Pharma

Among the research, chronic brand and leader pharma on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.

The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7.

Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore.

Roadmap: The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.

What to watch: Track new product launches, progress in the innovation pipeline and balance sheet strength.

Why Mankind Pharma Features Among These Research, Chronic Brand and Leader Pharma

Among the emerging market brands, chronic therapies and specialty shares on this list, Mankind Pharma is one of India's largest pharmaceutical companies by domestic sales, with a strong presence in chronic and acute therapies, consumer healthcare brands and a large field force.

Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%.

In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0.

Roadmap: The company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.

What to watch: Watch the market share in chronic therapies and the integration of acquired brands.

Why Sun Pharma Features Among These Research, Chronic Brand and Leader Pharma

Among the three companies on this list, Sun Pharmaceutical Industries is India's largest pharmaceutical company by market value, with branded generics in India, generics in the United States and a growing specialty medicines business for skin and eye care.

In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%.

Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2.

Roadmap: The company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.

What to watch: Track specialty product launches, United States approvals and domestic prescription trends.

Glenmark Pharmaceuticals vs Mankind Pharma vs Sun Pharma on Key Financials

The table below sets the three research, chronic brand and leader pharma side by side on revenue, profit and margin, using reported figures.

Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. Sun Pharma has the largest FY26 revenue at Rs 61,674 crore, and Mankind Pharma shows the fastest revenue growth with a 16.4% compound annual rate. A useful habit with research, chronic brand and leader pharma is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Research, Chronic Brand and Leader Pharma

Every theme carries risks that deserve a check before any decision. For these research, chronic brand and leader pharma, the main points are: Long-term emerging market brands, chronic therapies and specialty shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Pricing pressure. Generic prices can change by market.
• Currency moves. Export earnings move with the rupee.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter research, chronic brand and leader pharma by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Research, Chronic Brand and Leader Pharma

Research, chronic brand and leader pharma work best when investors track growth, valuation and return on equity side by side. Glenmark Pharmaceuticals, Mankind Pharma and Sun Pharma each have a clear plan to expand. Based on the 27 October 2026 close, Glenmark Pharmaceuticals trades at Rs 2,300, Mankind Pharma at Rs 2,490 and Sun Pharma at Rs 1,757.5. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these research, chronic brand and leader pharma to a watchlist.

Download the Univest iOS App or Univest Android App to track research, chronic brand and leader pharma, set price alerts and get research-backed stock ideas.

What are research, chronic brand and leader pharma?

Ans. Research, chronic brand and leader pharma are listed pharmaceutical companies that sell branded generics in India and emerging markets, lead in chronic and acute therapies through a wide field force and run branded, generics and specialty businesses. Their earnings depend on brand strength, launches and approvals. This list looks at three of them, Glenmark Pharmaceuticals, Mankind Pharma and Sun Pharma, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.

Which research, chronic brand and leader pharma are covered in this list?

Ans. This list covers Glenmark Pharmaceuticals, Mankind Pharma and Sun Pharma. Based on the 27 October 2026 close, Glenmark Pharmaceuticals traded at Rs 2,300, Mankind Pharma at Rs 2,490 and Sun Pharma at Rs 1,757.5. Their return on equity ranges from 11.7% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 16.4%.

Why do research, chronic brand and leader pharma have a strong future roadmap in India?

Ans. Research, chronic brand and leader pharma have a strong roadmap in India because chronic disease care, rising healthcare spending and wider access to medicines in smaller towns keep widening the market for Indian pharmaceutical firms. The main drivers are as follows. Brand strength. Trusted names drive repeat prescriptions. Wider reach. Field forces serve smaller towns. Specialty growth. New launches broaden the product mix. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Glenmark Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.

How has Mankind Pharma performed financially?

Ans. Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.

How has Sun Pharma performed financially?

Ans. Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2. Looking ahead, the company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.

What risks should investors check before buying research, chronic brand and leader pharma?

Ans. Investors should check a few risks before buying research, chronic brand and leader pharma. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of research, chronic brand and leader pharma investment advice?

Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.